vs
Side-by-side financial comparison of MID PENN BANCORP INC (MPB) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $62.0M, roughly 1.5× MID PENN BANCORP INC). MID PENN BANCORP INC runs the higher net margin — 31.4% vs 25.0%, a 6.3% gap on every dollar of revenue. On growth, MID PENN BANCORP INC posted the faster year-over-year revenue change (30.8% vs 23.3%). MID PENN BANCORP INC produced more free cash flow last quarter ($71.8M vs $12.8M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 21.1%).
Commerce Bancorp was a Cherry Hill, New Jersey–based bank created in 1973. In 2007, it was purchased by Toronto-Dominion Bank, which merged Commerce into TD Banknorth, the latter of which was rebranded to TD Bank.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
MPB vs VCEL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.0M | $92.9M |
| Net Profit | $19.4M | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 43.6% | 24.1% |
| Net Margin | 31.4% | 25.0% |
| Revenue YoY | 30.8% | 23.3% |
| Net Profit YoY | 47.0% | 17.3% |
| EPS (diluted) | $0.83 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.0M | $92.9M | ||
| Q3 25 | $61.8M | $67.5M | ||
| Q2 25 | $54.3M | $63.2M | ||
| Q1 25 | $47.7M | $52.6M | ||
| Q4 24 | $47.4M | $75.4M | ||
| Q3 24 | $45.3M | $57.9M | ||
| Q2 24 | $44.1M | $52.7M | ||
| Q1 24 | $42.3M | $51.3M |
| Q4 25 | $19.4M | $23.2M | ||
| Q3 25 | $18.3M | $5.1M | ||
| Q2 25 | $4.8M | $-553.0K | ||
| Q1 25 | $13.7M | $-11.2M | ||
| Q4 24 | $13.2M | $19.8M | ||
| Q3 24 | $12.3M | $-901.0K | ||
| Q2 24 | $11.8M | $-4.7M | ||
| Q1 24 | $12.1M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 43.6% | 24.1% | ||
| Q3 25 | 39.3% | 5.1% | ||
| Q2 25 | 7.9% | -3.2% | ||
| Q1 25 | 35.2% | -24.3% | ||
| Q4 24 | 34.1% | 24.5% | ||
| Q3 24 | 32.8% | -4.3% | ||
| Q2 24 | 32.4% | -11.5% | ||
| Q1 24 | 34.8% | -10.7% |
| Q4 25 | 31.4% | 25.0% | ||
| Q3 25 | 29.6% | 7.5% | ||
| Q2 25 | 8.8% | -0.9% | ||
| Q1 25 | 28.8% | -21.4% | ||
| Q4 24 | 27.9% | 26.3% | ||
| Q3 24 | 27.1% | -1.6% | ||
| Q2 24 | 26.7% | -8.9% | ||
| Q1 24 | 28.7% | -7.5% |
| Q4 25 | $0.83 | $0.46 | ||
| Q3 25 | $0.79 | $0.10 | ||
| Q2 25 | $0.22 | $-0.01 | ||
| Q1 25 | $0.71 | $-0.23 | ||
| Q4 24 | $0.72 | $0.40 | ||
| Q3 24 | $0.74 | $-0.02 | ||
| Q2 24 | $0.71 | $-0.10 | ||
| Q1 24 | $0.73 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $814.1M | $354.6M |
| Total Assets | $6.1B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M | ||
| Q1 24 | — | $110.6M |
| Q4 25 | $814.1M | $354.6M | ||
| Q3 25 | $796.3M | $321.9M | ||
| Q2 25 | $775.7M | $306.8M | ||
| Q1 25 | $667.9M | $295.5M | ||
| Q4 24 | $655.0M | $292.0M | ||
| Q3 24 | $573.1M | $257.5M | ||
| Q2 24 | $559.7M | $243.0M | ||
| Q1 24 | $551.0M | $233.9M |
| Q4 25 | $6.1B | $488.0M | ||
| Q3 25 | $6.3B | $453.3M | ||
| Q2 25 | $6.4B | $435.6M | ||
| Q1 25 | $5.5B | $424.6M | ||
| Q4 24 | $5.5B | $432.7M | ||
| Q3 24 | $5.5B | $390.4M | ||
| Q2 24 | $5.4B | $376.8M | ||
| Q1 24 | $5.3B | $356.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.0M | $15.0M |
| Free Cash FlowOCF − Capex | $71.8M | $12.8M |
| FCF MarginFCF / Revenue | 115.8% | 13.8% |
| Capex IntensityCapex / Revenue | 13.3% | 2.4% |
| Cash ConversionOCF / Net Profit | 4.12× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $132.1M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.0M | $15.0M | ||
| Q3 25 | $26.3M | $22.1M | ||
| Q2 25 | $29.0M | $8.2M | ||
| Q1 25 | $11.5M | $6.6M | ||
| Q4 24 | $51.4M | $22.2M | ||
| Q3 24 | $16.9M | $10.2M | ||
| Q2 24 | $18.0M | $18.5M | ||
| Q1 24 | $12.4M | $7.2M |
| Q4 25 | $71.8M | $12.8M | ||
| Q3 25 | $24.3M | $19.5M | ||
| Q2 25 | $27.2M | $81.0K | ||
| Q1 25 | $8.8M | $-7.6M | ||
| Q4 24 | $44.5M | $8.5M | ||
| Q3 24 | $16.8M | $-9.2M | ||
| Q2 24 | $17.7M | $1.8M | ||
| Q1 24 | $12.1M | $-6.8M |
| Q4 25 | 115.8% | 13.8% | ||
| Q3 25 | 39.4% | 28.8% | ||
| Q2 25 | 50.1% | 0.1% | ||
| Q1 25 | 18.4% | -14.5% | ||
| Q4 24 | 93.8% | 11.2% | ||
| Q3 24 | 37.1% | -15.9% | ||
| Q2 24 | 40.2% | 3.4% | ||
| Q1 24 | 28.5% | -13.3% |
| Q4 25 | 13.3% | 2.4% | ||
| Q3 25 | 3.1% | 3.9% | ||
| Q2 25 | 3.2% | 12.9% | ||
| Q1 25 | 5.7% | 27.0% | ||
| Q4 24 | 14.6% | 18.3% | ||
| Q3 24 | 0.0% | 33.5% | ||
| Q2 24 | 0.7% | 31.8% | ||
| Q1 24 | 0.8% | 27.3% |
| Q4 25 | 4.12× | 0.65× | ||
| Q3 25 | 1.44× | 4.35× | ||
| Q2 25 | 6.08× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 3.88× | 1.12× | ||
| Q3 24 | 1.37× | — | ||
| Q2 24 | 1.53× | — | ||
| Q1 24 | 1.02× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MPB
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
